Regulatory Advocacy
Regulatory Advocacy
NKF policy staff routinely comment on regulatory proposals and issue policy statements on important topics that affect kidney patients.
Recent Statements
Our most recent statements are listed below but please check out our blog for the latest news.
Latest Regulatory Comments
- Comments on OPTN Minimum Criteria Kidney Biopsy- March 2022
- Comments on OPTN eGFR Criteria – March 2022
- Comments on Medicare Advantage Advance Notice – March, 2022
- Letter to CMS Office of the Administrator - September 21, 2021
- Physician Fee Schedule - September 13, 2021
- CY2022 ESRD Rule and QIP - August 30, 2021
- Comments to NASEM - August 14, 2021
- IPPS - June 28, 2021
- Comments to MPSC - May 28, 2021
- Letter to CDC - May 18, 2021
- OPTN Strategic Plan - March 23, 2021
- Letter to HRSA on Kidney Health Evaluation - January 25, 2021
- Letter to ACIP - January 23, 2021
NKF Policy Statements
- Letter to the Medicare Administrative Contractors supporting increased access to cystatin C testing - April 2022
- Nephrology Community Joint Letter to HHS on Dialysis Shortages and Evusheld Access – January 2022
- Statement on Dialysis for the Undocumented - September 2021
- Letter to Health Resources & Services Administration – January 25, 2021
- Advisory Committee on Immunization Practices Letter – January 24, 2021
- Medicare Physician Fee Schedule – October 10, 2020
